A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat

Acta Neurochirurgica

Volumn 154, Issue 12, 2012, Pages 2215-2223

  Cho, Dae Chul ^a   Kim, Kyoung Tae ^a   Jeon, Younghoon ^b   Sung, Joo Kyung ^a,c  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

Author keywords

Alendronate; Curcumin; Micro computed tomography; Osteoporosis; Ovariectomy; Rat

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; CURCUMIN; OSTEOCALCIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; LUMBAR VERTEBRA; MECHANICAL TORSION; MICRO-COMPUTED TOMOGRAPHY; MONOTHERAPY; MORPHOMETRICS; MUSCULOSKELETAL SYSTEM EXAMINATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; THREE POINT BENDING TEST;

ALENDRONATE; ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; CURCUMIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; LUMBAR VERTEBRAE; OSTEOCALCIN; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871054046     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-012-1516-9     Document Type: Article

References (26)

1. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, Papadimitropoulos EA, Hopman W, Poliquin S, Prior JC, Hanley DA, Olszynski WP, Anastssiades T, Brown JP, Murray T, Jackson SA, Tenenhouse A, Canadian Multicentre Osteoporosis Study (CaMos) Research Group (2001) The influence of osteoporotic fractures on health-related quality of life in communitydwelling men and women across Canada. Osteoporos Int 12 (11): 903-908
2. Bell NH (2003) RANK ligand and the regulation of skeletal remodeling. J Clin Invest 111(8): 1120-1122
3. Bharti AC, Takada Y, Aggarwal BB (2004) Curcumin (diferuloylmethane) inhibits receptor activator of NF-kB ligandinduced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172(10): 5940-5947
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3): 465-475
5. Canpolat S, Tug N, Seyran AD, Kumru S, Yilmaz B (2010) Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats. J Physiol Biochem 66(1): 23-28
6. Fleisch H (1998) Bisphosphonate: mechanisms of action. Endocr Rev 19: 80-100
7. French DL, Muir JM, Webber CE (2008) The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. Phytomedicine 15 (12): 1069-1078
8. Folwarczna J, Zych M, Trzeciak HI (2010) Effects of curcumin on the skeletal system in rats. Pharmacol Rep 62(5): 900-909
9. Joe B, Vijaykumar M, Lokesh BR (2004) Biological properties of curcumin-celluar and molecular mechanisms of action. Crit Rev Food Sci Nutr 44(2): 97-111
10. Kashii M, Hashimoto J, Nakano T, Umakoshi Y, Yoshikawa H (2008) Alendronate treatment promotes bone formation with a less anisotropic microstructure during intramembranous ossification in rats. J Bone Miner Metab 26(1): 24-33
11. Notoya M, Nishimura H, Woo JT, Nagai K, Ishihara Y, Hagiwara H (2006) Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol 534(1-3): 55-62
12. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (3): 1294-1301
13. Oh S, Kyung TW, Choi HS (2008) Curcumin inhibits osteoclastogenesis by decreasing receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow stromal cells. Mol Cells 26 (5): 486-489
14. Ott SM (2005) Long-term safety of bisphosphonates. J Clin Endocrinol Metab 90(3): 1897-1899
15. Ozaki K, Kawata Y, Amano S, Hanazawa S (2000) Stimulatory effect of curcumin on osteoclast apoptosis. Biochem Pharmacol 59 (12): 1577-1581
16. Park SB, Lee YJ, Chung CK (2010) Bone mineral density changes after ovariectomy in rats as an osteopenic model: stepwise description of double dorso-lateral approach. J Korean Neurosurg Soc 48 (4): 309-312
17. Park SK, Oh S, Shin HK, Kim SH, Ham J, Song JS, Lee S (2011) Synthesis of substitute triazolyl curcumin mimics that inhibit RANKL-induced osteoclastogenesis. Bioorg Med Chem Lett 21 (12): 3573-3577
18. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115(12): 3318-3325
19. Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A (2012) Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone 50(5): 1054-1063
20. Salari P, Abdollahi M (2012) Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back. J Pharm Pharm Sci 15(2): 305-317
21. Shishodia S, Sethi G, Aggarwal BB (2005) Curcumin: getting back to the roots. Ann N Y Acad Sci 1056: 206-217
22. Szulc P, Meunier PJ (2003) Synergistic effect of vitamin D and calcium in preventing proximal femoral fractures in older patients. Joint Bone Spine 70(3): 157-160
23. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95(4): 1555-1565
24. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteoporosis. N Engl J Med 349: 457-463
25. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH (2007) Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853: 183-189
26. Yang MW,Wang TH, Yan PP, Chu LW, Yu J, Gao ZD, Li YZ, Guo BL (2011) Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine 18(2-3): 205-213